Table 4 Summary of studies on prostate cancer treated with radiotherapy using hypofractionation
Author and publication, year | Technique | No. of patients | Stage T1–2 (%) | ADT (%) | Median follow-up (months) | Total dose (Gy) | Dose per fraction (Gy) | NTD2Gy (Gy2) | 5-year bRFS rate (%) | Rate of late GI events (%) | Rate of late GU events (%) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Grade ≥ 2 | Grade ≥ 3 | Grade ≥ 2 | Grade ≥ 3 | ||||||||||
Kupelian et al. [12], 2007 | IMRT | 770 | 95 | 60 | 45 | 70 | 2.5 | 80.0 | 83 | 4.5 | 1.4 | 5.3 | 0.1 |
Pollack et al. [13], 2013 | IMRT | 151 | 86 | 45 | 68.4 | 70.2 | 2.7 | 84.4 | 76.7 | 18.1 | 2 | 21.5 | 4 |
Arcangeli et al. [14], 2012 | 3D-CRT | 83 | 65 | 100 | 70 | 62 | 3.1 | 81.5 | 85 | 17 | 1.2 | 16 | 1.2 |
Kuban et al. [15], 2010 | IMRT | 102 | NR | 21 | 55.2 | 72 | 2.4 | 80.2 | 96 | 11 | 3 | 19 | 0 |
Lukka et al. [28], 2005 | 3D-CRT | 466 | 100 | 0 | 68.4 | 52.5 | 2.6 | 61.5 | 40 | NR | 1.3 | NR | 1.9 |
Yeoh et al. [29], 2011 | 2D, 3D-CRT | 108 | 100 | 0 | 90 | 55 | 2.75 | 66.8 | 55.9 | NR | NR | NR | NR |
Leborgne et al. [30], 2011 | 3D-CRT | 114 | 95.6 | NR | 49 | 60 63 | 3 or 3.15 | 77.1 or 83.7 | 89 | 4.4 | 0.9 | 4.4 | 1.8 |
Norkus et al. [31], 2009 | 3D-CRT | 47 | 98 | 0 | 12 | 57 | 3 (13 fraction) or 4.5 (4 fraction) | 81.0 | NA | NR | NR | NR | NR |
Dearnaley et al. [32], 2016 | IMRT | 1074 | 91 | 97 | 62.4 | 60 | 3 | 77.1 | 90.6 | 11.9 | < 1 | 11.7 | < 1 |
1077 | 90 | 97 | 57 | 73.3 | 85.9 | 11.3 | < 1 | 6.6 | 1 | ||||
IMRT | 407 | 48 | 66 | 60 | 64.6 | 3.4 | 90.4 | 80.5 | 21.9 | 3.3 | 41.3 | 19.0 | |
Lee et al. [35], 2016 | 3D-CRT or IMRT | 550 | 100 | 0 | 69.6 | 70 | 2.5 | 80.0 | 86.3 | 22.4 | 4.1 | 29.7 | 3.5 |
Present series | IMRT | 596 | 98 | 61 | 62 | 76.70 | 2.19 | 80.9 | 92.7 | 8.5 | 1.2 | 19.4 | 1.1 |